<DOC>
	<DOC>NCT00092690</DOC>
	<brief_summary>This study is to assess the safety and efficacy of an investigational drug as compared to an approved drug to reduce specific cholesterol levels.</brief_summary>
	<brief_title>MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)</brief_title>
	<detailed_description>The duration of treatment is 6 weeks.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Elevated cholesterol Unstable medical conditions or significant heart problems within 3 months prior to first study visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>